Literature DB >> 17118658

Poloxamer 188 failed to prevent exercise-induced membrane breakdown in mdx skeletal muscle fibers.

John G Quinlan1, Brenda L Wong, Richard T Niemeier, Alexandra S McCullough, Linda Levin, Martin Emanuele.   

Abstract

We sought to determine the effectiveness of poloxamer 188 (P188) in protecting dystrophin-deficient, mdx skeletal muscle fiber membrane against exercise-induced breaches. mdx mice were treated with either P188 or placebo via intraperitoneal injections and run on a treadmill for 60-90 min. Membrane breakdown was quantified in cross-sections of rectus femoris muscle pretreated with Evans blue dye (in vivo). The mean % dye-penetrated muscle in the P188 and placebo groups was not significantly different in each of three trials. These results contrast with a recent report of P188 being highly effective in protecting the stretch- and dobutamine-stressed mdx heart muscle. The most likely explanations for the disparity are: (1) the exercise stress we used was beyond the protective range of P188, (2) P188 delivery and serum concentration were sub-optimal, or (3) the mdx skeletal myopathy and cardiomyopathy have fundamentally different responses to treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17118658     DOI: 10.1016/j.nmd.2006.09.016

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  18 in total

1.  Focal but reversible diastolic sheet dysfunction reflects regional calcium mishandling in dystrophic mdx mouse hearts.

Authors:  Ya-Jian Cheng; Di Lang; Shelton D Caruthers; Igor R Efimov; Junjie Chen; Samuel A Wickline
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-07-09       Impact factor: 4.733

Review 2.  Poloxamer 188 (p188) as a membrane resealing reagent in biomedical applications.

Authors:  Joseph G Moloughney; Noah Weisleder
Journal:  Recent Pat Biotechnol       Date:  2012-12

3.  A high-content, high-throughput siRNA screen identifies cyclin D2 as a potent regulator of muscle progenitor cell fusion and a target to enhance muscle regeneration.

Authors:  Michael V Khanjyan; Jonathan Yang; Refik Kayali; Thomas Caldwell; Carmen Bertoni
Journal:  Hum Mol Genet       Date:  2013-04-23       Impact factor: 6.150

Review 4.  Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy.

Authors:  David G Allen; Nicholas P Whitehead; Stanley C Froehner
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

5.  Torn apart: membrane rupture in muscular dystrophies and associated cardiomyopathies.

Authors:  Jan Lammerding; Richard T Lee
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

6.  Exosome-mediated improvement in membrane integrity and muscle function in dystrophic mice.

Authors:  Ling Leng; Xue Dong; Xianjun Gao; Ning Ran; Mengyuan Geng; Bingfeng Zuo; Yingjie Wu; Wei Li; Hua Yan; Gang Han; HaiFang Yin
Journal:  Mol Ther       Date:  2020-12-15       Impact factor: 11.454

7.  Affinity for, and localization of, PEG-functionalized silica nanoparticles to sites of damage in an ex vivo spinal cord injury model.

Authors:  Bojun Chen; Mahvash Zuberi; Richard Ben Borgens; Youngnam Cho
Journal:  J Biol Eng       Date:  2012-09-14       Impact factor: 4.355

8.  Experimental models of duchenne muscular dystrophy: relationship with cardiovascular disease.

Authors:  Venus Ameen; Lesley G Robson
Journal:  Open Cardiovasc Med J       Date:  2010-11-26

9.  Membrane sealant Poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice.

Authors:  Christopher F Spurney; Alfredo D Guerron; Qing Yu; Arpana Sali; Jack H van der Meulen; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  BMC Cardiovasc Disord       Date:  2011-05-16       Impact factor: 2.298

10.  Pharmacological therapeutics targeting the secondary defects and downstream pathology of Duchenne muscular dystrophy.

Authors:  Janelle M Spinazzola; Louis M Kunkel
Journal:  Expert Opin Orphan Drugs       Date:  2016-10-18       Impact factor: 0.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.